Equities analysts expect Evolus Inc (NASDAQ:EOLS) to announce ($0.82) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Evolus’ earnings. The lowest EPS estimate is ($1.23) and the highest is ($0.61). Evolus posted earnings per share of ($0.30) in the same quarter last year, which suggests a negative year-over-year growth rate of 173.3%. The firm is expected to issue its next earnings results on Thursday, May 9th.

On average, analysts expect that Evolus will report full year earnings of ($3.45) per share for the current financial year, with EPS estimates ranging from ($4.12) to ($2.91). For the next year, analysts expect that the firm will report earnings of ($1.56) per share, with EPS estimates ranging from ($1.75) to ($1.37). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Evolus.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Monday, March 18th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.09.

EOLS has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Evolus in a research report on Thursday, April 4th. Zacks Investment Research cut Evolus from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. Stifel Nicolaus initiated coverage on Evolus in a research report on Monday, January 28th. They issued a “buy” rating and a $27.00 price objective for the company. SunTrust Banks initiated coverage on Evolus in a research report on Wednesday, March 20th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $30.71.

Several hedge funds have recently made changes to their positions in EOLS. Wells Fargo & Company MN increased its position in shares of Evolus by 860.3% in the third quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock valued at $110,000 after buying an additional 5,325 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Evolus by 24.7% in the third quarter. Alliancebernstein L.P. now owns 22,200 shares of the company’s stock valued at $413,000 after buying an additional 4,400 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Evolus by 32.6% in the third quarter. Bank of New York Mellon Corp now owns 20,367 shares of the company’s stock valued at $379,000 after buying an additional 5,005 shares in the last quarter. BlackRock Inc. increased its position in shares of Evolus by 104.9% in the third quarter. BlackRock Inc. now owns 615,719 shares of the company’s stock valued at $11,465,000 after buying an additional 315,210 shares in the last quarter. Finally, Credit Suisse AG increased its position in shares of Evolus by 70.4% in the third quarter. Credit Suisse AG now owns 16,291 shares of the company’s stock valued at $303,000 after buying an additional 6,730 shares in the last quarter. Institutional investors and hedge funds own 19.82% of the company’s stock.

NASDAQ:EOLS opened at $24.98 on Thursday. Evolus has a 1 year low of $6.75 and a 1 year high of $39.50.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: Cost of Debt

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.